Microsoft clearly has an expressed interest in the expansion of their life sciences division as indicated by the asset acquisition of Rosetta Biosoftware.  Rosetta is a subsidiary of Merck & Co., Inc.  Microsoft will be rolling Rosetta’s generic and data into their Amalga Life Sciences software.  Through the acquisition, Merck will become a customer of Amalga.

“This agreement establishes a stable and sustainable platform for the Rosetta Biosoftware technology,” stated Merck Research Laboratories VP Rupert Vessey.

The deal will most likely close at the end of this month and the combined technologies should be available sometime in early 2010.

[via CNET]

Related Posts:

• November 18, 2009 -- T-Mobile Begins Selling Sidekicks Again
• November 17, 2009 -- Microsoft Employees Break Out In Dance [Video]
• November 17, 2009 -- Microsoft Windows 7 Could Contain Advertisements Built-In
• November 16, 2009 -- Laid Off Microsoft Evangelist Don Dodge Becomes Google Apps Evangelist
• November 12, 2009 -- Call Of Duty: Modern Warfare 2 Earns $310 Million In 24 Hours